Problems in treatment using sulfonylurea drugs and other existing oral antidiabetic agents or insulin typically include weight gain and hypoglycemia, but when incretin formulations are administered alone, the risk of weight gain and hypoglycemia is known to be low [8, 9]. This evidence concerns the gene INS and Hypoglycemia.